Reduced SMAD4 Expression in Gliomas and Its Impact on Patient Survival
Author Information
Author(s): He Shi-ming, Zhao Zhen-wei, Wang Yuan, Zhao Ji-pei, Wang Liang, Hou Fang, Gao Guo-dong
Primary Institution: Department of Neurosurgery, Institute for functional neurosurgery P.L.A, TangDu Hospital, Fourth Military Medical University, Xi'an, PR China
Hypothesis
The expression of SMAD4 at gene and protein levels in glioma samples correlates with survival outcomes.
Conclusion
Lower levels of SMAD4 expression are associated with poorer outcomes in glioma patients.
Supporting Evidence
- SMAD4 expression was decreased in glioma compared to normal brain tissues.
- SMAD4 mRNA and protein levels were both lower in glioma compared to control.
- Survival rates were higher for SMAD4-positive patients than for SMAD4-negative patients.
- Loss of SMAD4 was identified as a significant and independent prognostic indicator.
Takeaway
This study found that patients with lower SMAD4 levels in their gliomas tend to do worse than those with higher levels.
Methodology
The study analyzed 252 glioma specimens and 42 normal control tissues using immunochemistry, quantitative real-time PCR, and Western blot analysis.
Participant Demographics
Patients included 138 males and 114 females, with ages ranging from under 55 to over 55.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website